Arya Sobhakumari*1, Kevin P. Orcutt†‡1, Laurie Love-Homan§, Christopher E. Kowalski†‡, Arlene D. Parsons†, C. Michael Knudson†‡§¶, Andrean L. Simons*†‡§¶
Oncology Research, Vol.24, No.1, pp. 55-64, 2016, DOI:10.3727/096504016X14586627440192
Abstract Poor tumor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a significant challenge for effective treatment of head and neck squamous cell carcinoma (HNSCC). Therefore,
strategies that may increase tumor response to EGFR TKIs are warranted in order to improve HNSCC patient
treatment and overall survival. HNSCC tumors are highly glycolytic, and increased EGFR signaling has been
found to promote glucose metabolism through various mechanisms. We have previously shown that inhibition of glycolysis with 2-deoxy-d-glucose (2DG) significantly enhanced the antitumor effects of cisplatin and
radiation, which are commonly used to treat… More >
Login
Register
